Leier C V, Huss P, Lewis R P, Unverferth D V
Circulation. 1982 Jun;65(7):1382-7. doi: 10.1161/01.cir.65.7.1382.
Continuous 72-hour infusions of dobutamine reportedly effect sustained clinical improvement in patients with congestive heart failure. This study was designed to determine if shorter, more frequent infusions, delivered in an outpatient setting, elicit a similar response. Twenty-six patients with moderately severe congestive heart failure were randomized, 11 into a control group and 15 into a dobutamine treatment group. Baseline data were collected for 4 weeks in each group. Thereafter, the dobutamine treatment group received 4-hour infusions of dobutamine weekly for 24 weeks. Systolic time intervals, echocardiography, cardiac index and treadmill exercise tolerance were used to follow the progress of the control and dobutamine treatment groups. The ratio of preejection period to left ventricular ejection time and the cardiac index did not change significantly in either group. The velocity of circumferential fiber shortening and the percent change in the minor axis of the left ventricle during systole improved modestly (p less than 0.05) above baseline in the dobutamine group after 14 weeks of treatment and above the corresponding control values (p less than 0.05) after 22 weeks. Exercise tolerance (duration) improved 25--51% (all p less than 0.05) above baseline in the dobutamine group compared with 10--17% (all p greater than 0.05 vs baseline) in the control group. Heart rate at maximal exercise did not change significantly from baseline for either group and did not differ significantly between the two groups. Functional classification improved in 12 of 15 dobutamine treatment patients and in only two of 11 control patients (p less than 0.05). In our patients with congestive heart failure, weekly 4-hour dobutamine infusions did not elicit a major change in resting left ventricular function; however, exercise performance and clinical status improved considerably.
据报道,连续72小时静脉输注多巴酚丁胺可使充血性心力衰竭患者的临床症状持续改善。本研究旨在确定在门诊环境中进行更短、更频繁的输注是否能产生类似的效果。26例中度严重充血性心力衰竭患者被随机分组,11例进入对照组,15例进入多巴酚丁胺治疗组。每组收集4周的基线数据。此后,多巴酚丁胺治疗组每周接受4小时的多巴酚丁胺输注,共24周。通过收缩期时间间期、超声心动图、心脏指数和跑步机运动耐量来跟踪对照组和多巴酚丁胺治疗组的进展。两组的射血前期与左心室射血时间之比和心脏指数均无显著变化。多巴酚丁胺组在治疗14周后,圆周纤维缩短速度和收缩期左心室短轴变化百分比较基线适度改善(p<0.05),在22周后高于相应的对照组值(p<0.05)。多巴酚丁胺组的运动耐量(持续时间)较基线提高了25%-51%(所有p<0.05),而对照组为10%-17%(与基线相比所有p>0.05)。两组最大运动时的心率与基线相比均无显著变化,两组之间也无显著差异。15例多巴酚丁胺治疗患者中有12例功能分级改善,而11例对照组患者中只有2例改善(p<0.05)。在我们的充血性心力衰竭患者中,每周4小时的多巴酚丁胺输注并未引起静息左心室功能的重大变化;然而,运动能力和临床状况有相当大的改善。